ML
MLAB.US Mesa Laboratories Inc
- Market cap
- USD 781M
- P/E
- 119.8x
- P/B
- 4.02x
- ROE
- 7.4%
- Dividend yield
- 0.45%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is MLAB.US undervalued?
Graham numberThe Graham number of Mesa Laboratories Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mesa Laboratories Inc fundamental analysis
No fundamental analysis for Mesa Laboratories Inc yet.
Mesa Laboratories Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mesa Laboratories Inc
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.…
Full company profileMesa Laboratories Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Mesa Laboratories Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 93.7M | 96.2M | 103M | 118M | 134M | 184M | 219M | 216M | 241M | 249M | 245M |
| Gross Profit | 53.2M | 54.6M | 60.9M | 65.4M | 87.0M | 109M | 134M | 133M | 151M | 158M | 158M |
| Operating Income | 16.3M | 2.18M | 9.78M | 7.92M | 12.4M | 4.70M | 3.32M | -272M | 16.3M | 18.5M | 30.8M |
| EBITDA | 25.1M | 9.77M | 35.4M | 22.4M | 28.0M | 32.5M | 37.5M | -238M | 42.3M | 35.3M | 52.2M |
| Net Income | 11.2M | -2.96M | 7.48M | 1.78M | 3.27M | 1.87M | 930K | -254M | -1.97M | 6.71M | 14.3M |
| EPS | 2.91 | -0.79 | 1.86 | 0.41 | 0.64 | 0.35 | 0.17 | -47 | -0.36 | 1.21 | 2.49 |
| Balance Sheet | |||||||||||
| Total Assets | 172M | 164M | 157M | 420M | 601M | 707M | 662M | 447M | 433M | 428M | 408M |
| Total Liabilities | 73.9M | 64.7M | 45.5M | 200M | 195M | 314M | 268M | 301M | 274M | 242M | 213M |
| Shareholders' Equity | 97.8M | 99.4M | 111M | 220M | 406M | 394M | 393M | 145M | 160M | 186M | 195M |
| Cash & Short-term Investments | 5.82M | 5.47M | 10.2M | 81.4M | 264M | 49.3M | 32.9M | 28.2M | 27.3M | 26.9M | 22.3M |
| Total Debt | 54.8M | 46.3M | 22.7M | 141M | 147M | 221M | 186M | 231M | 181M | 169M | 82.3M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 7.75M | 24.8M | 30.6M | 26.6M | 37.1M | 39.2M | 28.0M | 44.1M | 46.8M | 42.8M | 37.7M |
| Capital Expenditure | 11.6M | 2.80M | 1.26M | 1.50M | 1.99M | 4.43M | 4.54M | 2.57M | 4.50M | 3.25M | 1.89M |
| Free Cash Flow | -3.86M | 22.0M | 29.3M | 25.1M | 35.1M | 34.8M | 23.4M | 41.6M | 42.3M | 39.6M | 35.8M |
| Ratios | |||||||||||
| ROE | 11.4% | -3.0% | 6.7% | 0.8% | 0.8% | 0.5% | 0.2% | -174.9% | -1.2% | 3.6% | 7.4% |
| ROA | 6.5% | -1.8% | 4.8% | 0.4% | 0.5% | 0.3% | 0.1% | -56.9% | -0.5% | 1.6% | 3.5% |
| Net Profit Margin | 11.9% | -3.1% | 7.3% | 1.5% | 2.4% | 1.0% | 0.4% | -117.6% | -0.8% | 2.7% | 5.9% |
| Debt to Equity | 0.56x | 0.47x | 0.20x | 0.64x | 0.36x | 0.56x | 0.47x | 1.59x | 1.14x | 0.91x | 0.42x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Mesa Laboratories Inc dividends
- Dividend yield
- 0.45%
- Forward dividend
- 0.64 USD
- Payout ratio
- 52.5%
- Ex-dividend date
- Nov 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 3.52M | 0.63 | 52.5% |
| 2025 | USD 3.47M | 0.64 | - |
| 2024 | USD 3.45M | 0.64 | - |
| 2023 | USD 3.41M | 0.64 | 366.2% |
| 2022 | USD 3.34M | 0.63 | 178.5% |
| 2021 | USD 3.17M | 0.62 | 96.7% |
| 2020 | USD 2.72M | 0.62 | 153.1% |
| 2019 | USD 2.46M | 0.61 | 32.9% |
| 2018 | USD 2.41M | 0.64 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Mesa Laboratories Inc
- Insiders 5.78%
- Institutions 94.22%
- Public & others 0.00%
- Shares outstanding 5.62M
- Free float 4.97M
Top funds holding MLAB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| SSGA State Street Em Mkts Opps Eq I USD | 296K | 5.27% | 0.00% | Oct 2026 |
| Victory Sycamore Small Company Opp R | 215K | 3.83% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 169K | 3.00% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 138K | 2.46% | 0.00% | Oct 2026 |
| Wasatch Small Cap Value | 121K | 2.15% | 0.00% | Sep 2026 |
| Diamond Hill Small Cap Inv | 90.5K | 1.61% | -12.00% | Oct 2026 |
| Fidelity Small Cap Index | 59.1K | 1.05% | +1.15% | Aug 2026 |
| William Blair Small Cap Value I | 56.3K | 1.00% | +189.04% | Sep 2026 |
| Crawford Small Cap Dividend | 56.1K | 1.00% | -5.88% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 55.6K | 0.99% | +0.27% | Oct 2026 |
| Keeley Gabelli Small Cap Dividend I | 54.0K | 0.96% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 50.8K | 0.91% | -0.38% | Oct 2026 |
| Herald Ord | 50.0K | 0.89% | 0.00% | Mar 2026 |
| Wasatch Micro Cap Value | 46.8K | 0.83% | -25.16% | Sep 2026 |
| Bridge Builder Small Cap Fund | 43.0K | 0.77% | +3.04% | Oct 2026 |
| Vanguard Russell 2000 ETF | 31.5K | 0.56% | +2.54% | Sep 2026 |
| Janus Henderson Small Cap Gr Alpha ETF | 31.0K | 0.55% | 0.00% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 30.0K | 0.53% | +0.21% | Oct 2026 |
| Principal US Small Cap ETF | 29.5K | 0.52% | +0.05% | Oct 2026 |
| Russell Inv US Small Cap Equity Y | 28.9K | 0.51% | -4.20% | Sep 2026 |
Top institutions holding MLAB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Long Path Partners, LP | 477K | 8.50% | +17.64% | Jun 2026 |
| BlackRock Inc | 441K | 7.85% | +11.86% | Jun 2026 |
| Boston Partners Global Investors, Inc | 265K | 4.72% | -1.33% | Jun 2026 |
| Vanguard Capital Management, LLC | 237K | 4.23% | +2.07% | Jun 2026 |
| AQR Capital Management LLC | 204K | 3.63% | +19.45% | Jun 2026 |
| Ranger Investment Management LP | 174K | 3.10% | -14.25% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 164K | 2.92% | +10.45% | Sep 2026 |
| Morgan Stanley - Brokerage Accounts | 157K | 2.80% | -3.17% | Jun 2026 |
| Diamond Hill Capital Management, LLC | 156K | 2.77% | +0.30% | Jun 2026 |
| Geode Capital Management, LLC | 140K | 2.49% | +9.12% | Jun 2026 |
| Kennedy Capital Management Inc | 138K | 2.46% | -2.84% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 131K | 2.33% | +194.57% | Jun 2026 |
| State Street Corp | 124K | 2.21% | +1.82% | Jun 2026 |
| Wasatch Advisors LP | 116K | 2.06% | +125.77% | Jun 2026 |
| Royce & Associates, LP | 113K | 2.02% | -29.67% | Jun 2026 |
| Crawford Investment Counsel, Inc | 98.8K | 1.76% | +3.42% | Jun 2026 |
| FMR Inc | 88.9K | 1.58% | +1,273.37% | Jun 2026 |
| D. E. Shaw & Co LP | 81.8K | 1.46% | +49.85% | Jun 2026 |
| Jane Street Group LLC | 71.6K | 1.28% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 69.4K | 1.24% | +31.88% | Jun 2026 |
Mesa Laboratories Inc company profile
- Company name
- Mesa Laboratories Inc
- Ticker
- MLAB.US
- Exchange
- USA Stocks
- Listed since
- Jan 25, 1995
- Sector
- Technology
- Industry
- Life Sciences Tools & Services
- Employees
- 717
- Fiscal year end
- March
- Address
- 12100 West Sixth Avenue, Lakewood, CO, United States, 80228
- Phone
- 303 987 8000
- Website
- mesalabs.com
About Mesa Laboratories Inc
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides sterility assurance testing and laboratory services to the dental and pharmaceutical industries. The Biopharmaceutical Development segment develops, manufactures, sells, and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for hereditary disease screenings, pharmacogenetics, oncology related applications, and toxicology research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; and PurePep Symphony and Chorus instruments for peptide synthesis. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as renal care, gas flow, environmental and process monitoring, and torque testing in pharmaceutical, laboratory, medical device, manufacturing, industrial, and environmental applications. This segment's products include continuous monitoring systems, data loggers, and torque testing systems under the DialyGuard, DryCal, DataTrace, and ViewPoint brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Mesa Laboratories Inc management
4- Mr. John V. Sakys CPAVP & CFO · born 1969
- Mr. Brian David ArchboldSenior Vice President of Operations & Continuous Improvement · born 1975
- Dr. Siddhartha Chandrakant Kadia B.E., M.S., Ph.D.CEO, President & Director · born 1970
- Ms. Lyndsey CrennenChief Accounting Officer · born 1985